Clinical Trial

Improving Total Shoulder Arthroplasty

Study Description

Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

This is a phase IV , randomized, single-blind, single-center study comparing patient related outcomes such as postoperative pain and opioid usage for patients who receive ISB 's containing liposomal bupivacaine (ExparelAR) plus 0.5% bupivacaine HCL versus 0.5% bupivacaine HCL undergoing total shoulder arthroplasty. The objective of this study is to compare opioid utilization and pain management of patients who receive Exparel in an ISB vs standard 0.5% bupivacaine HCL during the initial 72 --a?? hour post --a?? operative period. Additionally, to understand the duration of block after addition of ExparelAR to bupivacaine in an Interscalene block after TSA.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Liposomal Bupivacaine

Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL

Drug - 0.5% Bupivacaine HCL

0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)

Additional Information

Official Study Title

Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

Clinical Trial ID

NCT03913091

ParticipAid ID

dPN96a